Investor Stock List
Ranked #6,563 of 8,699 institutional investors

Royalty Pharma Sub-Manager, LLC

New York, NY

$178M
US stock portfolio at live prices · today −$3.7M (−2.02%)
Market closed. Prices as of Nov 20, 6:41 AM ET
Value at quarter end (Q3 2026)
$196M
Change from Q2 2026
−$45.6M (−18.87%)
Positions
3 · 0 new, 0 sold out
Filed
Nov 13, 2026

Not counted in the ranking: none$39.2M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
ZBIO 33.6%CYTK 28.4%KLRA 16.0%
StockSharesValue, live% of portfoliovs Q2 2026
ZBIO Zenas BioPharma, Inc.2,388,150$59.8M33.6%Unchanged
CYTK Cytokinetics, Incorporated980,392$50.5M28.4%Unchanged
KLRA Kailera Therapeutics, Inc.2,455,357$28.4M16.0%Unchanged